Michael S Brown Regeneron Pharmaceuticals, Inc. (REGN) insider trading activity

Michael S Brown is Director of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 1,382 shares of REGN, which is worth approximately $970,979. The most recent transaction as insider was on Jun 14, 2024, when has been sold 1,535 shares (Common Stock) at a price of $1040.0 per share, resulting in proceeds of $1,596,400. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.38K

0% 3M change

10.83% 12M change

Total Value Held $970,979

MICHAEL S BROWN Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 14 2024	SELL Open market or private sale	$1,596,400 $1040.0 p/Share	1,535 Reduced 52.62%	1,382 Common Stock
Jun 14 2024	BUY Exercise of conversion of derivative security	$960,296 $625.6 p/Share	1,535 Added 34.48%	2,917 Common Stock
May 28 2024	SELL Open market or private sale	$1,142,535 $974.86 p/Share	1,172 Reduced 45.89%	1,382 Common Stock
May 28 2024	BUY Exercise of conversion of derivative security	$733,203 $625.6 p/Share	1,172 Added 31.45%	2,554 Common Stock
Jan 02 2024	BUY Grant, award, or other acquisition	-	135 Added 8.9%	1,382 Common Stock
Dec 27 2023	SELL Open market or private sale	$1,840,002 $898.0 p/Share	2,049 Reduced 62.17%	1,247 Common Stock
Dec 27 2023	BUY Exercise of conversion of derivative security	$989,011 $482.68 p/Share	2,049 Added 38.33%	3,296 Common Stock
Apr 21 2023	SELL Open market or private sale	$2,451,149 $798.42 p/Share	3,070 Reduced 71.11%	1,247 Common Stock
Apr 21 2023	BUY Exercise of conversion of derivative security	$1,596,430 $520.01 p/Share	3,070 Added 41.56%	4,317 Common Stock
Feb 06 2023	SELL Open market or private sale	$2,450,658 $798.0 p/Share	3,071 Reduced 71.12%	1,247 Common Stock
Feb 06 2023	BUY Exercise of conversion of derivative security	$1,596,950 $520.01 p/Share	3,071 Added 41.56%	4,318 Common Stock
Jan 27 2023	SELL Open market or private sale	$747 $747.0 p/Share	1 Reduced 0.08%	1,247 Common Stock
Jan 27 2023	BUY Exercise of conversion of derivative security	$520 $520.01 p/Share	1 Added 0.08%	1,248 Common Stock
Jan 06 2023	SELL Open market or private sale	$2,293,719 $747.14 p/Share	3,070 Reduced 71.11%	1,247 Common Stock
Jan 06 2023	BUY Exercise of conversion of derivative security	$1,596,430 $520.01 p/Share	3,070 Added 41.56%	4,317 Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	-	165 Added 11.69%	1,247 Common Stock
Nov 08 2022	SELL Open market or private sale	$3,035,321 $759.78 p/Share	3,995 Reduced 78.69%	1,082 Common Stock
Nov 08 2022	BUY Exercise of conversion of derivative security	$1,711,458 $428.4 p/Share	3,995 Added 54.67%	3,313 Common Stock
Mar 30 2022	SELL Open market or private sale	$285,192 $699.0 p/Share	408 Reduced 27.38%	1,082 Common Stock
Mar 30 2022	BUY Exercise of conversion of derivative security	$152,641 $374.12 p/Share	408 Added 21.5%	1,490 Common Stock
Mar 29 2022	SELL Open market or private sale	$1,063,878 $699.0 p/Share	1,522 Reduced 58.45%	1,082 Common Stock
Mar 29 2022	BUY Exercise of conversion of derivative security	$569,411 $374.12 p/Share	1,522 Added 36.89%	2,604 Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	191 Added 15.0%	1,082 Common Stock
Sep 13 2021	SELL Open market or private sale	$6,253,937 $644.47 p/Share	9,704 Reduced 91.59%	891 Common Stock
Sep 13 2021	BUY Exercise of conversion of derivative security	$3,906,248 $402.54 p/Share	9,704 Added 47.81%	10,595 Common Stock

MSB

Michael S Brown

Director

Tarrytown, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Value

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

Operation

Value

Type

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Track Activities on REGN

Account